GeneDx Holdings Past Earnings Performance
Past criteria checks 0/6
GeneDx Holdings's earnings have been declining at an average annual rate of -24.4%, while the Healthcare industry saw earnings growing at 7.1% annually. Revenues have been growing at an average rate of 6.5% per year.
Key information
-24.4%
Earnings growth rate
150.4%
EPS growth rate
| Healthcare Industry Growth | 8.5% |
| Revenue growth rate | 6.5% |
| Return on equity | -77.1% |
| Net Margin | -86.8% |
| Next Earnings Update | 29 Apr 2024 |
Recent past performance updates
Recent updates
Further Upside For GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Introduce Price Risks After 42% Bounce
Apr 24
GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13
Feb 23The Market Lifts GeneDx Holdings Corp. (NASDAQ:WGS) Shares 107% But It Can Do More
Feb 22Improved Revenues Required Before GeneDx Holdings Corp. (NASDAQ:WGS) Stock's 56% Jump Looks Justified
Dec 20Analyst Forecasts Just Became More Bearish On GeneDx Holdings Corp. (NASDAQ:WGS)
Nov 02Not Many Are Piling Into GeneDx Holdings Corp. (NASDAQ:WGS) Stock Yet As It Plummets 49%
Nov 01Sema4 names Kevin Feeley as CFO
Aug 26Things Look Grim For Sema4 Holdings Corp. (NASDAQ:SMFR) After Today's Downgrade
Aug 20Sema4 Holdings Corp. (NASDAQ:SMFR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 19Sema4 Q2 2022 Earnings Preview
Aug 12Sema4 Holdings, Big Data For Precision Medicine Solutions
Jul 18Revenue & Expenses BreakdownBeta
How GeneDx Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 203 | -176 | 195 | 58 |
| 30 Sep 23 | 206 | -459 | 231 | 70 |
| 30 Jun 23 | 236 | -494 | 278 | 69 |
| 31 Mar 23 | 224 | -533 | 330 | 79 |
| 31 Dec 22 | 235 | -549 | 338 | 86 |
| 30 Sep 22 | 231 | -280 | 357 | 84 |
| 30 Jun 22 | 191 | -170 | 332 | 89 |
| 31 Mar 22 | 202 | -131 | 259 | 73 |
| 31 Dec 21 | 212 | -245 | 324 | 105 |
| 30 Sep 21 | 218 | -331 | 328 | 114 |
| 30 Jun 21 | 214 | -420 | 305 | 115 |
| 31 Mar 21 | 197 | -406 | 291 | 113 |
| 31 Dec 20 | 179 | -241 | 173 | 73 |
| 31 Dec 19 | 196 | -33 | 78 | 35 |
| 31 Dec 18 | 133 | -27 | 49 | 21 |
Quality Earnings: WGS is currently unprofitable.
Growing Profit Margin: WGS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: WGS is unprofitable, and losses have increased over the past 5 years at a rate of 24.4% per year.
Accelerating Growth: Unable to compare WGS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: WGS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (7.3%).
Return on Equity
High ROE: WGS has a negative Return on Equity (-77.09%), as it is currently unprofitable.